



DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

Multiple Studies of DNAtrix Oncolytic Viruses to be Presented at the SNO Annual Meeting

Houston, TX – November 15, 2018 – DNAtrix, a leader in oncolytic virus immunotherapies for cancer, will present interim results from the ongoing Phase 2 trial of its oncolytic virus DNX-2401 (tasadenoturev) with pembrolizumab for patients with recurrent glioblastoma at the upcoming 2018 Annual Meeting of the Society for Neuro-Oncology (SNO) which is being held in New Orleans, Louisiana from November 15th - 18th.

CAPTIVE / KEYNOTE-192 is a Phase 2 multicenter, dose escalation study evaluating a single intratumoral injection of DNX-2401 followed by standard dosing with pembrolizumab every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma. Preliminary results demonstrate that DNX-2401 with pembrolizumab is well tolerated, and associated with promising survival.

“I am excited by the early results of the trial. We have had some very remarkable responses. If I had not done the case myself, I would not have believed the complete response we have seen in one of our patients,” said Gelareh Zadeh, MD, Associate Professor at the Department of Surgery University of Toronto, and presenting author for the CAPTIVE / KEYNOTE-192 study.

“There are limited treatment options for patients with this devastating disease, and we are encouraged by the initial data showing safety and disease control with the combination of DNX-2401 and pembrolizumab,” added Frank Tufaro, PhD, CEO of DNAtrix. “We are pleased that enrollment is nearly complete and we are looking forward to maturation of the survival data.”

DNAtrix collaborators will present additional results from studies of DNX-2401 (a.k.a. Delta-24-RGD) and murine DNX-2440 (a.k.a. Delta-24-RGDOX), an oncolytic adenovirus expressing the immune modulator OX40 ligand. Details of the presentations are as follows:

Interim results of a phase II multicenter study of the conditionally replicative oncolytic adenovirus DNX-2401 with pembrolizumab (Keytruda) for recurrent glioblastoma; CAPTIVE Study (KEYNOTE-192)

Date: Saturday, November 17

Abstract Number: ATIM-24

Presenter: Gelareh Zadeh, MD, University Health Network, University of Toronto, Toronto, ON, Canada

[To access the abstract, click here >](#)

Inflammatory reprogramming of gliomas using Delta-24-RGDOX and immunometabolic adjuvants

Date: Friday, November 16

Abstract Number: EXTH-27

Presenter: Teresa Nguyen, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[To access the abstract, click here >](#)

Local oncolytic adenovirus treatment affects both the innate and adaptive arms of the immune system and provides an avenue for enhancing immunotherapies for GBM

Date: Friday, November 16

Abstract Number: EXTH-03

Presenter: Martine Lamfers, PhD, Erasmus Medical Center, Rotterdam, Netherlands

[To access the abstract, click here >](#)

In Situ Autovaccination Mediated by Oncolytic Adenovirus Delta-24-RGDOX Induces Efficacious Immunity Against Metastatic Melanoma

Date: Saturday, November 17

Abstract Number: EXTH-30

Presenter: Hong Jiang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[To access the abstract, click here >](#)

Delta-24-RGD in combination with positive regulators of the immune synopsis for gliomas in adults and children

Date: Sunday, November 18

Oral Presentation: Juan Fueyo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

For more information about ongoing DNATRIX clinical studies, visit the ClinicalTrials.gov

website: [NCT03714334](#) (DNX-2440 for recurrent glioblastoma), [NCT02798406](#) (DNX-2401 + pembrolizumab for recurrent glioblastoma), and [NCT03178032](#) (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma, DIPG).

About DNX-2401 (Tasadenoturev)

DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. Previous studies demonstrated that DNX-2401 was well tolerated, provided clinical benefit, and extended survival for patients with recurrent glioblastoma.

About DNATRIX

DNATRIX is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. Its oncolytic adenovirus platform viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNATRIX has multiple virus candidates in clinical trials for cancers with urgent needs for novel approaches. For more information, please visit the company website at <https://www.DNATRIX.com>.

Contact

DNATRIX

Imran Alibhai, Ph.D.

S.V.P. Business Development

ialibhai@dnatrix.com

Source: <https://www.dnatrix.com/view.cfm/117/2018-press-release>

November 15th 2018